Green Cross Corporation (006280.KS)
KRW 168000.0
(-1.7%)
KRW 168000.0
(-1.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 109.81 Billion KRW | -36.65% |
| 2022 | 187.04 Billion KRW | -25.39% |
| 2021 | 159.01 Billion KRW | 174.31% |
| 2020 | 168.79 Billion KRW | 6.05% |
| 2019 | 57.8 Billion KRW | -11.1% |
| 2018 | 97.77 Billion KRW | -21.49% |
| 2017 | 115.05 Billion KRW | -1.8% |
| 2016 | 115.84 Billion KRW | -29.27% |
| 2015 | 120.08 Billion KRW | 12.62% |
| 2014 | 120.26 Billion KRW | 54.03% |
| 2013 | 97.23 Billion KRW | 5.02% |
| 2012 | 90.41 Billion KRW | -12.09% |
| 2011 | 102.49 Billion KRW | -36.1% |
| 2010 | 159.3 Billion KRW | 18.19% |
| 2009 | 130.95 Billion KRW | 160.13% |
| 2008 | 76.37 Billion KRW | -18.73% |
| 2007 | 64.41 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 17.6 Billion KRW | 273.94% |
| 2024 Q1 | 4.7 Billion KRW | -55.61% |
| 2024 Q3 | 39.6 Billion KRW | 125.0% |
| 2023 Q1 | 99.46 Billion KRW | 1401.51% |
| 2023 Q2 | 6.27 Billion KRW | -93.69% |
| 2023 FY | - KRW | -36.65% |
| 2023 Q4 | 10.6 Billion KRW | -92.47% |
| 2023 Q3 | 140.85 Billion KRW | 2144.67% |
| 2022 Q3 | 74.73 Billion KRW | 122.29% |
| 2022 Q4 | 6.62 Billion KRW | -91.14% |
| 2022 Q2 | 33.61 Billion KRW | -42.39% |
| 2022 FY | - KRW | -25.39% |
| 2022 Q1 | 58.36 Billion KRW | -26.38% |
| 2021 Q2 | 27.39 Billion KRW | -14.1% |
| 2021 Q4 | 79.27 Billion KRW | -15.45% |
| 2021 FY | - KRW | 174.31% |
| 2021 Q3 | 93.75 Billion KRW | 242.23% |
| 2021 Q1 | 31.88 Billion KRW | 275.67% |
| 2020 FY | - KRW | 6.05% |
| 2020 Q1 | 16.94 Billion KRW | 247.65% |
| 2020 Q4 | -18.15 Billion KRW | -128.84% |
| 2020 Q3 | 62.94 Billion KRW | 174.33% |
| 2020 Q2 | 22.94 Billion KRW | 35.41% |
| 2019 Q2 | 22.98 Billion KRW | 41.8% |
| 2019 FY | - KRW | -11.1% |
| 2019 Q1 | 16.21 Billion KRW | 180.41% |
| 2019 Q3 | 52.13 Billion KRW | 126.81% |
| 2019 Q4 | -11.47 Billion KRW | -122.01% |
| 2018 Q2 | 25.98 Billion KRW | 5.39% |
| 2018 Q4 | 5.78 Billion KRW | -82.7% |
| 2018 FY | - KRW | -21.49% |
| 2018 Q1 | 24.65 Billion KRW | 1180.0% |
| 2018 Q3 | 33.41 Billion KRW | 28.6% |
| 2017 Q4 | 1.92 Billion KRW | -96.12% |
| 2017 Q3 | 49.57 Billion KRW | 10.86% |
| 2017 Q1 | 18.19 Billion KRW | -45.24% |
| 2017 FY | - KRW | -1.8% |
| 2017 Q2 | 44.71 Billion KRW | 145.82% |
| 2016 FY | - KRW | -29.27% |
| 2016 Q3 | 36.51 Billion KRW | 21.75% |
| 2016 Q2 | 29.99 Billion KRW | 78.67% |
| 2016 Q1 | 16.78 Billion KRW | 163.72% |
| 2016 Q4 | 33.22 Billion KRW | -9.02% |
| 2015 FY | - KRW | 12.62% |
| 2015 Q4 | 6.36 Billion KRW | -93.24% |
| 2015 Q3 | 94.15 Billion KRW | 127.0% |
| 2015 Q2 | 41.47 Billion KRW | 82.61% |
| 2015 Q1 | 22.71 Billion KRW | 40.88% |
| 2014 FY | - KRW | 54.03% |
| 2014 Q4 | 16.12 Billion KRW | -75.23% |
| 2014 Q3 | 65.1 Billion KRW | 175.07% |
| 2014 Q2 | 23.66 Billion KRW | -42.79% |
| 2014 Q1 | 41.37 Billion KRW | 465.9% |
| 2013 Q3 | 48.26 Billion KRW | 132.49% |
| 2013 Q4 | 7.31 Billion KRW | -84.86% |
| 2013 Q1 | 18.61 Billion KRW | 606.72% |
| 2013 FY | - KRW | 5.02% |
| 2013 Q2 | 20.76 Billion KRW | 11.56% |
| 2012 Q3 | 47.93 Billion KRW | 138.74% |
| 2012 FY | - KRW | -12.09% |
| 2012 Q4 | -3.67 Billion KRW | -107.66% |
| 2012 Q1 | 26.06 Billion KRW | 100.54% |
| 2012 Q2 | 20.07 Billion KRW | -22.99% |
| 2011 FY | - KRW | -36.1% |
| 2011 Q4 | 12.99 Billion KRW | -73.83% |
| 2011 Q2 | 18.87 Billion KRW | -12.36% |
| 2011 Q1 | 21.53 Billion KRW | 0.0% |
| 2011 Q3 | 49.68 Billion KRW | 163.22% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 24.75 Billion KRW | -74.15% |
| 2010 Q1 | 95.76 Billion KRW | 38.69% |
| 2010 FY | - KRW | 18.19% |
| 2010 Q3 | 41.71 Billion KRW | 68.52% |
| 2009 Q1 | 8.24 Billion KRW | -22.83% |
| 2009 Q3 | 31.93 Billion KRW | 18.53% |
| 2009 Q4 | 69.04 Billion KRW | 116.21% |
| 2009 Q2 | 26.94 Billion KRW | 226.96% |
| 2009 FY | - KRW | 160.13% |
| 2008 Q3 | 10.93 Billion KRW | -26.01% |
| 2008 FY | - KRW | -18.73% |
| 2008 Q1 | 15.95 Billion KRW | 147.67% |
| 2008 Q2 | 14.77 Billion KRW | -7.36% |
| 2008 Q4 | 10.67 Billion KRW | -2.35% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q1 | 17.83 Billion KRW | 0.0% |
| 2007 Q2 | 18.27 Billion KRW | 2.45% |
| 2007 Q3 | 21.86 Billion KRW | 19.67% |
| 2007 Q4 | 6.44 Billion KRW | -70.54% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | -600.899% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | -64.285% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 0.0% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | -1201.015% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 272.39% |
| Celltrion, Inc. | 897.26 Billion KRW | 87.762% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 93.152% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | -382.111% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 594.535% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 453.684% |